Pila Pharma: Initial results from the 13-week safety study

Research Note



Redeye feels encouraged that the preclinical preparations of XEN-DIA keep progressing according to plan. We leave a short comment.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.